Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INDUCE trial of upadacitinib versus prednisolone for inflammatory bowel disease flares
ACTRN12625000861459Phase 4Not yet recruiting
- Sponsor
- Mater Misericordiae University Hospital
- Start
- Oct 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in inflammatory bowel disease (IBD), autoimmune colitis and Crohn's disease comparing Upadacitinib with Prednisolone (2 arms). Planned start Oct 2025; status: not yet recruiting.
02
Drugs
upadacitinibprednisolone
03
Conditions
inflammatory bowel disease (IBD)autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on ACTRN12625000861459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000861459.